

Meeting Notice of 2024 Annual Shareholders' Meeting

- It is hereby scheduled at 9:00 a.m. on June 14, 2024 (Friday) (the registration time for shareholders is 30 minutes before the start of the meeting), at 8th Floor, No. 97, Section 1, Xintai 5th Road, Xizhi District, New Taipei City (the company's conference room), to hold the annual shareholders' meeting 2024. Main contents of the meeting: (1) Reporting matters: 1. 2023 Annual business report. 2. The audit committee reviews the 2023 annual final accounts report. 3. The report on the implementation of the sound business plan. (2) Recognition matters: 1.2023 Annual business report and financial statements. 2. 2023 Annual loss allocation proposal. 3. The company is handling the 2019-year the second domestic guaranteed conversion of corporate bonds, and plans to carry out a plan change case. (3) Election matters: The tenth director election. (4) Other Proposals: Lifting the non-competition restrictions on the company's new directors and their representatives. (5) Extemporary Motions.
- The Company adopted the candidate nomination system for electing the 7 directors (including 3 independent directors). The list of director candidates is Tong- Hsuan Chang, TAIWAN ADVANCE BIO-PHARMACEUTICAL INC., Hsiu-E Su, Mei-Chun Yang. The list of independent director candidates is Ling-Chun Tsai, Kuang-Yang Hsu, Johnson Lin. Please referto Market Observation Post Systemat (https://mops.twse.com.tw/mops/web/t146sb10) for the educational background and experience relevant information.
- ≥ \ If the Company decides to hold a meeting under Article 172 of the Company Law, electronic files will be posted to the Market Observation Post System at https://emops.twse.com.tw. Please select "Shareholders' Meetings" under the "Electronic Books" tab, enter the year, and click "GO" to find the meeting files corresponding to Company code.
- 四、According to Article 165 of the Company Law, stock transfers will be suspended from April 16, 2024 to June 14, 2024.
- 五、Please find enclosed the "Notice of Attendance" and "Proxy Statement." If you intend to personally attend the meeting, please

sign or place your seal in the "Registration Card" column. Shareholders may sign or place their seal in the "Proxy Statement" column to appoint a proxy to attend the meeting on his or her behalf and execute power of attorney in writing. Please fill in the "Proxy Statement" and deliver to the Company's stock agency, Grand Fortune Securities Co., Ltd. Transfer Agent, no later than, Jun 7, 2024, 5 days prior to the meeting date.

- ∴ The company will compile a summary statement of the relevant information provided by shareholders through solicitation of the proxy and disclose the content in the website of Securities & Futures Institute (SFI) on May 14, 2024. Shareholders can navigate to SFI's web page (https://free.sfi.org.tw) to view relevant information. (TWSE code:4168)
- to Jun 11, 2024. Please log in the "Stockvote" (https://www.stockvote.com.tw) of Taiwan Depository & Clearing Corporation (TDCC) and vote in.
- harpoonup. It is highly appreciated that you handle the matters accordingly.

To Shareholders

The Board of Directors of GlycoNex Inc Co.,Ltd.